Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19
Coronavirus disease 2019 (COVID-19) is a clinical syndrome caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients with severe disease show hyperactivation of the immune system, which can affect multiple organs besides the lungs. Here, we propose that SARS-CoV-2 infection induces a process known as immunothrombosis, in which activated neutrophils and monocytes interact with platelets and the coagulation cascade, leading to intravascular clot formation in small and larger vessels. Microthrombotic complications may contribute to acute respiratory distress syndrome (ARDS) and other organ dysfunctions. Therapeutic strategies aimed at reducing immunothrombosis may therefore be useful. Several antithrombotic and immunomodulating drugs have been proposed as candidates to treat patients with SARS-CoV-2 infection. The growing understanding of SARS-CoV-2 infection pathogenesis and how it contributes to critical illness and its complications may help to improve risk stratification and develop targeted therapies to reduce the acute and long-term consequences of this disease.
| Errataetall: |
CommentIn: Intern Emerg Med. 2022 Mar;17(2):593-596. - PMID 34677789 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Nature reviews. Immunology - 21(2021), 5 vom: 06. Mai, Seite 319-329 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bonaventura, Aldo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Fibrinolytic Agents |
|---|
| Anmerkungen: |
Date Completed 19.05.2021 Date Revised 31.03.2022 published: Print-Electronic CommentIn: Intern Emerg Med. 2022 Mar;17(2):593-596. - PMID 34677789 Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41577-021-00536-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32379789X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32379789X | ||
| 003 | DE-627 | ||
| 005 | 20231225184943.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41577-021-00536-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1079.xml |
| 035 | |a (DE-627)NLM32379789X | ||
| 035 | |a (NLM)33824483 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bonaventura, Aldo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.05.2021 | ||
| 500 | |a Date Revised 31.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Intern Emerg Med. 2022 Mar;17(2):593-596. - PMID 34677789 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Coronavirus disease 2019 (COVID-19) is a clinical syndrome caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients with severe disease show hyperactivation of the immune system, which can affect multiple organs besides the lungs. Here, we propose that SARS-CoV-2 infection induces a process known as immunothrombosis, in which activated neutrophils and monocytes interact with platelets and the coagulation cascade, leading to intravascular clot formation in small and larger vessels. Microthrombotic complications may contribute to acute respiratory distress syndrome (ARDS) and other organ dysfunctions. Therapeutic strategies aimed at reducing immunothrombosis may therefore be useful. Several antithrombotic and immunomodulating drugs have been proposed as candidates to treat patients with SARS-CoV-2 infection. The growing understanding of SARS-CoV-2 infection pathogenesis and how it contributes to critical illness and its complications may help to improve risk stratification and develop targeted therapies to reduce the acute and long-term consequences of this disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Fibrinolytic Agents |2 NLM | |
| 700 | 1 | |a Vecchié, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Dagna, Lorenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Martinod, Kimberly |e verfasserin |4 aut | |
| 700 | 1 | |a Dixon, Dave L |e verfasserin |4 aut | |
| 700 | 1 | |a Van Tassell, Benjamin W |e verfasserin |4 aut | |
| 700 | 1 | |a Dentali, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Montecucco, Fabrizio |e verfasserin |4 aut | |
| 700 | 1 | |a Massberg, Steffen |e verfasserin |4 aut | |
| 700 | 1 | |a Levi, Marcel |e verfasserin |4 aut | |
| 700 | 1 | |a Abbate, Antonio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature reviews. Immunology |d 2001 |g 21(2021), 5 vom: 06. Mai, Seite 319-329 |w (DE-627)NLM117889695 |x 1474-1741 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2021 |g number:5 |g day:06 |g month:05 |g pages:319-329 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41577-021-00536-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2021 |e 5 |b 06 |c 05 |h 319-329 | ||